低分子量氨酸降低了临床MSC产品中的前凝剂活性
Jacob B Schriner1, Fabio Triolo2, Brijesh S Gill3
1Department of Surgery, Center for Translational Injury Research, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Cytotherapy
|December 21, 2023
概括
低分子量肝素 (LMWH) 降低了与间酶体 stromal 细胞 (MSCs) 治疗相关的血栓风险. 这项研究表明,LMWH在所有测试的MSC类型中有效降低了血栓生成,这表明静脉注射是一种更安全的方法.
科学领域:
- 细胞生物学 细胞生物学
- 血液学 血液学 血液学
- 生物医学工程 生物医学工程
背景情况:
- 介酶体 stromal 细胞 (MSC) 是用于治疗的多能成年干细胞.
- 组织因子 (TF) 在MSCs上的表达可以促进血栓形成 (血栓发生性).
- 血管内注射MSC带有风险,例如静脉血栓栓塞 (VTE).
研究的目的:
- 调查低分子量肝素 (LMWH) 对临床级MSCs的血栓发生率的影响.
- 评估LMWH在MSC治疗期间减轻VTE风险的潜力.
主要方法:
- 使用了来自骨髓,脂肪和带的临床级MSC.
- 校准自动血栓学 (CAT) 测量了血栓生成 (TG).
- 在MSC化时,LMWH的度各不相同.
主要成果:
- MSCs增加了血栓的生成,这表明有潜在的前凝性.
- 在所有MSC类型中,LMWH显著降低了TG,以剂量依赖的方式.
- 脂肪酸衍生的MSCs (MSC(AT)) 显示出对LMWH的最小血栓发生率和最高灵敏度.
结论:
- 在实验室中,LMWH有效地降低了介质细胞 stromal 细胞的血栓发生率.
- LMWH是一种有前途的药物,可以减轻与静脉MSC注射相关的VTE风险.
- 需要进一步的体内研究来确定最佳的LMWH剂量和对炎症反应的影响.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
706
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
706
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:16Clot Retraction and Fibrinolysis
6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.9K